Immune Design Corp. (NASDAQ:IMDZ) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $7.42 and last traded at $7.42, with a volume of 94,181 shares changing hands. The stock had previously closed at $8.05.

IMDZ has been the subject of a number of research reports. Wells Fargo & Co. reissued a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Leerink Swann reissued a “buy” rating on shares of Immune Design Corp. in a research note on Friday, June 10th. Zacks Investment Research lowered shares of Immune Design Corp. from a “buy” rating to a “hold” rating in a research note on Friday, May 13th. Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Finally, Jefferies Group reissued a “buy” rating and set a $20.00 target price on shares of Immune Design Corp. in a research note on Wednesday, May 11th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $24.00.

The stock’s 50 day moving average is $9.90 and its 200-day moving average is $12.05. The firm’s market capitalization is $148.12 million.

Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.61) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.01. On average, equities research analysts forecast that Immune Design Corp. will post ($2.70) earnings per share for the current year.

Other institutional investors have made changes to their positions in the company. Jennison Associates LLC raised its position in shares of Immune Design Corp. by 0.4% in the fourth quarter. Jennison Associates LLC now owns 203,452 shares of the company’s stock valued at $4,085,000 after buying an additional 769 shares in the last quarter. Oxford Asset Management purchased a new stake in shares of Immune Design Corp. during the fourth quarter valued at approximately $1,166,000. Finally, Jennison Associates increased its stake in shares of Immune Design Corp. by 0.6% in the third quarter. Jennison Associates now owns 202,683 shares of the company’s stock valued at $2,473,000 after buying an additional 1,224 shares during the last quarter.

Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.